Patents by Inventor Tatsuya KAWATO

Tatsuya KAWATO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-GDF15 ANTIBODY
    Publication number: 20230036655
    Abstract: The present disclosure includes an anti-hGDF15 antibody that binds to an epitope of hGDF15 comprising the amino acid sequence of DHCPLGPGRCCRLH (SEQ ID NO: 3) and uses thereof.
    Type: Application
    Filed: December 3, 2020
    Publication date: February 2, 2023
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Shigeki NISHIHARA, Yuichi ISHIKAWA, Yuichiro NAKAISHI, Tatsuya KAWATO
  • Modified biotin, streptavidin mutant, and usage of them
    Patent number: 11286285
    Abstract: An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, and usage of them.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 29, 2022
    Assignee: SAVID THERAPEUTICS INC.
    Inventors: Akira Sugiyama, Hirofumi Doi, Tatsuhiko Kodama, Tsuyoshi Inoue, Eiichi Mizohata, Tatsuya Kawato, Tomohiro Meshizuka, Motomu Kanai, Yohei Shimizu, Noriaki Takasu, Mari Takatsu
  • Modified biotin, streptavidin mutant, and usage of them
    Patent number: 11161884
    Abstract: An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: November 2, 2021
    Assignee: SAVID THERAPEUTICS INC.
    Inventors: Akira Sugiyama, Hirofumi Doi, Tatsuhiko Kodama, Tsuyoshi Inoue, Eiichi Mizohata, Tatsuya Kawato, Tomohiro Meshizuka, Motomu Kanai, Yohei Shimizu, Noriaki Takasu, Mari Takatsu
  • Modified biotin, streptavidin mutant, and usage of them
    Patent number: 11124549
    Abstract: An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: September 21, 2021
    Assignee: SAVID THERAPEUTICS INC.
    Inventors: Akira Sugiyama, Hirofumi Doi, Tatsuhiko Kodama, Tsuyoshi Inoue, Eiichi Mizohata, Tatsuya Kawato, Tomohiro Meshizuka, Motomu Kanai, Yohei Shimizu, Noriaki Takasu, Mari Takatsu
  • MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM
    Publication number: 20200017558
    Abstract: An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.
    Type: Application
    Filed: July 16, 2019
    Publication date: January 16, 2020
    Applicant: SAVID THERAPEUTICS INC.
    Inventors: Akira SUGIYAMA, Hirofumi DOI, Tatsuhiko KODAMA, Tsuyoshi INOUE, Eiichi MIZOHATA, Tatsuya KAWATO, Tomohiro MESHIZUKA, Motomu KANAI, Yohei SHIMIZU, Noriaki TAKASU, Mari TAKATSU
  • Modified biotin, mutant streptavidin, and use thereof
    Patent number: 9670255
    Abstract: It is an object of the present invention to provide a mutant streptavidin with a reduced affinity for natural biotin, and also to provide a modified biotin having a high affinity for the mutant streptavidin with a reduced affinity for natural biotin. According to the present invention, there is provided a reagent kit for use in treatments or diagnoses, which comprises: (a) a mutant streptavidin with a reduced affinity for natural biotin or biocytin; and a modified biotin having a high affinity for the above-described mutant streptavidin.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: June 6, 2017
    Assignee: SAVID THERAPEUTICS INC.
    Inventors: Akira Sugiyama, Hirofumi Doi, Tatsuhiko Kodama, Tsuyoshi Inoue, Eiichi Mizohata, Tatsuya Kawato, Tomohiro Meshizuka, Motomu Kanai, Yohei Shimizu, Tomohiro Yamamoto
  • MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM
    Publication number: 20170145063
    Abstract: An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, and usage of them.
    Type: Application
    Filed: February 18, 2015
    Publication date: May 25, 2017
    Applicant: SAVID THERAPEUTICS INC.
    Inventors: Akira SUGIYAMA, Hirofumi DOI, Tatsuhiko KODAMA, Tsuyoshi INOUE, Eiichi MIZOHATA, Tatsuya KAWATO, Tomohiro MESHIZUKA, Motomu KANAI, Yohei SHIMIZU, Noriaki TAKASU, Mari TAKATSU
  • MODIFIED BIOTIN, MUTANT STREPTAVIDIN, AND USE THEREOF
    Publication number: 20160137704
    Abstract: It is an object of the present invention to provide a mutant streptavidin with a reduced affinity for natural biotin, and also to provide a modified biotin having a high affinity for the mutant streptavidin with a reduced affinity for natural biotin. According to the present invention, there is provided a reagent kit for use in treatments or diagnoses, which comprises: (a) a mutant streptavidin with a reduced affinity for natural biotin or biocytin; and a modified biotin having a high affinity for the above-described mutant streptavidin.
    Type: Application
    Filed: February 18, 2014
    Publication date: May 19, 2016
    Applicant: SAVID THERAPEUTICS INC.
    Inventors: Akira SUGIYAMA, Hirofumi DOI, Tatsuhiko KODAMA, Tsuyoshi INOUE, Eiichi MIZOHATA, Tatsuya KAWATO, Tomohiro MESHIZUKA, Motomu KANAI, Yohei SHIMIZU, Tomohiro YAMAMOTO